Viking Therapeutics, Inc.的股价在11月3日美股夜盘交易中大涨20.86%,收于88.08美元。这主要得益于公司新型口服减肥药物VK2735在临床试验中取得了突破性进展。
在一项针对VK2735的临床试验中,服用100毫克剂量的受试患者在28天后平均减重8.2%,比安慰剂组高出6.8个百分点,疗效显著。更令人振奋的是,在最高剂量下没有患者中断治疗,表明该药具有良好的安全性和耐受性。
目前减肥药市场主要由诺和诺德和礼来等大型制药企业提供的注射剂量药物所主导。Viking的VK2735若顺利上市,将成为一款具有竞争力的口服剂型减肥药,为肥胖患者带来新的选择。分析师们看好该药物的发展前景,认为其具备挑战现有老牌企业的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.